
    
      This is a multicenter, prospective, observational study conducted to evaluate the safety of
      ADASUVE treatment when used in real-world clinical setting in patients with agitation
      associated with schizophrenia or bipolar I disorder.

      The primary objective of the study is to assess the safety of ADASUVE treatment in real-world
      clinical settings.

      The secondary objective of the study is to describe the characteristics of patients,
      including demographic and baseline characteristics, after administration of ADASUVE treatment
      in real-world clinical settings.

      The study population will consist of a non-randomized cohort of approximately 10000 adult men
      and women who have agitation associated with schizophrenia or bipolar I disorder (naïve and
      non-naïve to ADASUVE treatment).
    
  